31 Stocks Moving In Monday's Mid-Day Session

Gainers

  • AveXis, Inc. AVXS surged 77.8 percent to $206.07 after the company agreed to be acquired by Novartis AG NVS for $8.7 billion.
  • Turtle Beach Corporation HEAR shares jumped 46.1 percent to $3.74 after the company raised its guidance for the first quarter.
  • Therapix Biosciences Ltd. TRPX gained 31.8 percent to $6.5625 after the company disclosed topline results of Phase IIa study at Yale University for Tourette Syndrome program.
  • REGENXBIO Inc. RGNX gained 28.7 percent to $35.0095 after dropping 3.89 percent on Friday.
  • uniQure N.V. QURE shares gained 18 percent to $25.92.
  • Nemaura Medical Inc. NMRD shares jumped 16.3 percent to $3.85. Nemaura Medical named Bashir Timol as Chief Business Officer.
  • Aileron Therapeutics, Inc. ALRN shares rose 15.2 percent to $7.335.
  • Century Aluminum Company CENX shares surged 13.7 percent to $19.09
  • Audentes Therapeutics, Inc. BOLD gained 13.2 percent to $31.805 after dropping 2.87 percent on Friday.
  • Abeona Therapeutics Inc. ABEO rose 12.4 percent to $15.74.
  • Natera, Inc. NTRA climbed 11.7 percent to $9.8301. Natera named Paul R. Billings, M.D., Ph.D., as Chief Medical Officer. Craig-Hallum initiated coverage on Natera, with a Buy rating.
  • Spark Therapeutics, Inc. ONCE climbed 11.6 percent to $69.23.
  • Sage Therapeutics, Inc. SAGE shares gained 10.4 percent to $156.02.
  • Leucadia National Corporation LUK climbed 10.3 percent to $24.005 after the company agreed to sell 48 percent of National Beef for $1.05 billion and its stake in Garcadia for $425 million. The company also announced a 25 million share buyback plan.
  • Verastem, Inc. VSTM shares climbed 7.9 percent to $3.195 after the company disclosed that the FDA has accepted New Drug Application for duvelisib.
  • bluebird bio, Inc. BLUE shares gained 7.1 percent to $174.275 after falling 4.38 percent on Thursday.
  • argenx SE ARGX climbed 6.4 percent to $79.64. argenx named Keith Woods as Chief Operating Officer. SunTrust initiated coverage on argenx with a Buy rating.
  • Cellect Biotechnology Ltd. APOP gained 5 percent to $6.81. The Israel-based developer of a novel stem cell enabling technology said it has completed a proof of concept testing of its new product prototype called ApoTrainer, which is designed to replace procedures like bone marrow transplants.
  • Merck & Co., Inc. MRK rose 3.4 percent to $55.17 after the company disclosed that its KEYTRUDA monotherapey met its primary endpoint in the Phase 3 KEYNOTE-042 study.


Check out these big penny stock gainers and losers

Losers

  • Menlo Therapeutics Inc. MNLO dipped 71.6 percent to $10.00 as the company disclosed that its Phase 2 trial of serlopitant for pruritus associated with atopic dermatitis did not meet primary and key secondary efficacy endpoints.
  • ACADIA Pharmaceuticals Inc. ACAD shares dropped 21.5 percent to $16.91.
  • NMI Holdings, Inc. NMIH shares fell 20.2 percent to $14.12.
  • Mechel PAO MTL shares dipped 18.4 percent to $3.47.
  • MGIC Investment Corporation MTG shares dropped 14.9 percent to $10.91. MGIC Investment is expected to release its Q1 financial results on Wednesday, April 18, 2018.
  • Essent Group Ltd. ESNT shares dipped 14.1 percent to $36.15.
  • Radian Group Inc. RDN declined 13.8 percent to $16.50.
  • Schmitt Industries, Inc. SMIT fell 11.1 percent to $2.41. Schmitt reported Q3 earnings of $0.00 per share, versus a year-ago loss of $0.04 per share. Its total sales rose 1.2 percent to $3.23 million.
  • Twin Disc, Incorporated TWIN shares fell 9.9 percent to $20.49.
  • Yandex N.V. YNDX shares fell 9.3 percent to $35.71 after declining 1.84 percent on Friday.
  • SSLJ.com Limited SSLJ declined 7.2 percent to $4.825 after dropping 2.80 percent on Friday.
  • Marrone Bio Innovations, Inc. MBII shares fell 6.1 percent to $3.0524 after jumping 21.72 percent on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!